influenza np

This peptide is a H2-Db-restricted epitope from Influenza nucleoprotein (147-155).

This peptide is a H-2Kd-restricted epitope from Influenza nucleoprotein (147-155).

Influenza NP (311-325) is a biologically active peptide consisting of amino acids 311 to 325 from the influenza virus nucleoprotein (NP). As a bona fide MHC class II-restricted epitope, it is critical for studying host immune responses during viral infection, inducing robust gamma interferon (IFN-gamma) production in intracellular cytokine assays without stimulating CD8 T-cells in mice. The presence of Glutamine (Q) or Glutamic acid (E) at the N-terminus can lead to spontaneous formation of Pyroglutamyl (pGlu) peptides, enhancing peptide stability against gastrointestinal proteases. These peptides are considered a normal variant and included in peptide purity measurements in HPLC analysis.

Anti-Influenza A virus NP Antibody (H16-L10-4R5 (HB-65)) is a mouse-derived IgG2a kappa antibody designed to target the nucleoprotein of the influenza A virus. The recommended isotype control for this antibody is Mouse IgG2a kappa, Isotype Control.

CEF8, Influenza Virus NP (383-391), is an influenza A virus nucleoprotein containing residues 383 to 391, and it is the most important HLA-B*2705-restricted epitope in the nucleoprotein of influenza A viruses, associated with escape from cytotoxic T lymphocytes-mediated immunity. [HLA-B*3501 restricted influenza virus nucleoprotein epitope (383-391).]

HLA-B*08 restricted influenza virus nucleoprotein epitope.

This peptide is an H2-Db-restricted epitope from the Influenza A/PR/8/34 nucleoprotein.

Influenza A NP (383-391) (HLA-B27) is a peptide sequence derived from tetanus toxin. It serves as an epitope for CD4+ T helper cells, exhibiting broad immunogenic properties that enhance the response of CD8+ cytotoxic T lymphocytes (CTL). Additionally, this compound is utilized in the research of breast cancer.

ATV2301 is an orally potent anti-influenza compound with an EC50 of 1.88 nM for H1N1 and 4.77 nM for H3N2. Its anti-influenza activity results from its impact on polymerase acidic protein (PA), nucleoprotein (NP), and RNA-dependent RNA polymerase (RdRp).

VNT-101 is an orally active inhibitor of influenza A virus (IAV). It disrupts NP-NP protein interactions, preventing NP oligomerization and destabilizing the viral ribonucleoprotein (RNP) complex, showing potent antiviral activity against multiple influenza A virus subtypes. In cell-based cytopathic effect (CPE) assays, VNT-101 has an EC50 value of 4-5 nM, while it measures 4-8 nM in neuraminidase (NA) assays and 21-45 nM in ribonucleoprotein (RNP) assays. Demonstrating strong in vivo antiviral efficacy, VNT-101 protects against lethal H1N1 virus infection in mice. VNT-101 is applicable to influenza A virus infection research.

TTHP 512 is an inhibitor of influenza A virus (IAV) exhibiting significant antiviral activity with an IC50 value of 1.46 μM. It disrupts the viral replication process by inhibiting the expression of viral nucleoprotein (NP) and PB2 protein. TTHP 512 holds potential for research on influenza A virus.

RdRP-IN-4 (compound 11q) is an arylbenzohydrazide analogue, an orally active inhibitor of influenza A virus RNA-dependent RNA polymerase (RdRp) that directly binds the PB1 subunit of RdRp. RdRP-IN-4 inhibited H1N1 (A/PR/8/34) Flu A and Flu B strains (B/Lee/1940) in a dose-dependent manner with EC50 values of 53 nM and 20 nM, respectively. RdRP-IN-4 had a significant antiviral effect in infected mice.

BMS-883559 is a novel inhibitor of the influenza nucleoprotein (INF-NP).

Nucleozin targets influenza A nucleoprotein (NP), a multifunctional, RNA-binding protein necessary for virus replication.

Eleutheroside B1 mediates its anti-influenza activity through POLR2A and N-glycosylation. Eleutheroside B1 inhibits the mRNA expression of several chemokine genes and the influenza nucleoprotein (NP) gene, and exhibits low cytotoxicity. Antiviral and anti